目的:描述,分析比较西班牙药学服务门诊免疫介导的炎症性疾病患者在两个不同时期的药学服务咨询情况。
方法:纵向,多中心和单学科描述性观察研究,由西班牙医院药学学会免疫介导的炎症性疾病工作组通过2019年和2021年的虚拟调查进行。收集了关于协调的变量,资源,生物仿制药,未满足的需求和远程药房。数值结果以绝对值和百分比表示,自由文本响应按主题区域分组。要比较两个收集时间之间的结果,卡方检验的显著性水平为p<0.05。
结果:参与水平为2019年的70名药剂师和2021年的53名。获得的主要重要发现是增加了哮喘生物学委员会的参与(p=0.044)以及皮肤科(p=0.003)和消化系统(p=0.022)的护理协调。生物仿制药的广泛应用脱颖而出,参考生物与生物仿制药的交换增加了15%。该领域研究不足,人力资源不足,在其他未满足的需求中,被揭露。在门诊单位,MAPEX项目的分层模型的使用占少数,并促进了信息和通信技术的使用。受COVID-19引起的大流行的激励,85%的中心首次建立了远程药房,在第二次调查时将服务维持在66%。
结论:门诊单位正在不断变化以适应新时代,为此,需要机构支持投入更多资源,以促进制定减少未满足需求的战略。我们必须继续努力实现提高效率的制药实践,安全,免疫介导的炎性疾病患者的生活质量和获得创新药物。
OBJECTIVE: To describe, analyze and compare the situation of pharmaceutical care consultations for outpatients with immune-mediated inflammatory diseases of the Pharmacy Services of Spain at two different times.
METHODS: Longitudinal, multicenter and unidisciplinary descriptive observational study, carried out by the Immune-mediated Inflammatory Diseases Working Group of the Spanish Society of Hospital Pharmacy through a virtual survey in 2019 and 2021. Variables were collected regarding coordination, resources, biosimilars, unmet needs and telepharmacy. Numerical results were presented in absolute value and percentage and free text responses were grouped by topic areas. To compare the results between the two collection times, the Chi-Square test was used with a significance level of p<0.05.
RESULTS: The level of participation was 70 pharmacists in 2019 and 53 in 2021. The main significant findings obtained were an increase in participation in asthma biologic committees (p=0.044) and care coordination in dermatology (p=0.003) and digestive system (p=0.022). The wide use of biosimilar biological medicines stood out, with a 15% increase in the exchange of the reference biological to the biosimilar. The lack of research in the field and insufficient human resources, among other unmet needs, were revealed. In the outpatient units, the use of the stratification model of the MAPEX project was a minority and an increase in the use of information and communication technologies was promoted. Motivated by the pandemic derived from COVID-19, telepharmacy was established for the first time in 85% of the centers, maintaining the service at 66% at the time of the second survey.
CONCLUSIONS: Outpatient units are undergoing constant change to adapt to new times, for which institutional support is needed to invest more resources to promote the development of strategies to reduce unmet needs. We must continue working to achieve a pharmaceutical practice that provides efficiency, safety, quality of life and access to innovative drugs in patients with immune-mediated inflammatory diseases.